Amgen (AMGN) : Orbimed Advisors reduced its stake in Amgen by 1.54% during the most recent quarter end. The investment management company now holds a total of 2,876,000 shares of Amgen which is valued at $497,605,520 after selling 45,000 shares in Amgen , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Amgen makes up approximately 4.72% of Orbimed Advisors’s portfolio.
Other Hedge Funds, Including , Tanaka Capital Management Inc reduced its stake in AMGN by selling 1,800 shares or 34.5% in the most recent quarter. The Hedge Fund company now holds 3,418 shares of AMGN which is valued at $591,382. Amgen makes up approx 1.44% of Tanaka Capital Management Inc’s portfolio.San Francisco Sentry Investment Group (ca) reduced its stake in AMGN by selling 250 shares or 2.23% in the most recent quarter. The Hedge Fund company now holds 10,937 shares of AMGN which is valued at $1,884,883. Amgen makes up approx 1.11% of San Francisco Sentry Investment Group (ca)’s portfolio. Miracle Mile Advisors added AMGN to its portfolio by purchasing 1,509 company shares during the most recent quarter which is valued at $257,556. Amgen makes up approx 0.08% of Miracle Mile Advisors’s portfolio.Conestoga Capital Advisors reduced its stake in AMGN by selling 200 shares or 13.07% in the most recent quarter. The Hedge Fund company now holds 1,330 shares of AMGN which is valued at $220,341. Amgen makes up approx 0.02% of Conestoga Capital Advisors’s portfolio.
Amgen opened for trading at $170.55 and hit $170.56 on the upside on Thursday, eventually ending the session at $170.13, with a gain of 0.04% or 0.07 points. The heightened volatility saw the trading volume jump to 18,76,141 shares. Company has a market cap of $127,319 M.
On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.
Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.